Worldwide, there were more than ~400,000 new cases in 2020, and >175,000 people died from their disease (WHO, 2020).
Source: Globocan 2020
Renal cell carcinoma (RCC) is the most common form of kidney cancer. RCC is an increasingly frequent cancer, having more than doubled in incidence in the developed world over the last 50 years (Padala et al, World Journal of Oncology, 2020).
Carbonic Anhydrase IX (CAIX) is a cell-surface antigen and a cancer target that is overexpressed in renal cancer and a number of other cancers including bladder or urothelial, breast, brain, cervix, colon, oesophagus, head and neck, lung, ovarian, pancreatic and vulval.
Telix is investigating CAIX as a potential target for renal cancer theranostics and in other tumour types that are known to overexpress CAIX.
For more information on Telix’s active clinical trials in renal cancer please see trial descriptions below, clickable through to clinical trial database where registered.
A full listing of Telix clinical trials, which also includes active and completed studies can be found at ClinicalTrials.gov.
Molecularly targeted radiation can target a cell-surface antigen called Carbonic Anhydrase IX (CAIX), a cancer target that is overexpressed in some carcinomas due to a mutation of the von Hippel-Lindau (VHL) protein. It has overexpression in many types of cancer and low expression in normal tissues. CA is a transmembrane protein and a tumour-associated carbonic anhydraseisoenzyme. It shows high expression in carcinomas of the kidney, uterine cervix, oesophagus, lung, breast, colon, brain and vulva compared to expression in few non-cancerous tissue.
Professor Peter Mulders, Head of Urology at Radboud UMC, presents an overview of RCC and the imaging techniques used in diagnosis.
Hear from Professor Oliver Sartor, Medical Director Tulane Cancer Center, who explains more about Molecularly Targeted Radiation, also known as radioligand therapy, as well as Theranostics and the role of Carbonic Anhydrase (CAIX) in cancer cell targeting.